EDIT

NASDAQ open

Editas Medicine

1.65 USD
▼-0.06-3.51%
盘后 2.57 0.00%
2026-11-20
市值
$253.12M
市盈率
—
EPS
-0.62
股息率
—
52 周区间
1.65 – 3.94
成交量
1.31M
Beta
2.08
目标价
6.10
52W 低 1.6552W 高 3.94
价格走势

公司简介

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ...